Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 27, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...
August 11, 2025 06:00 ET | Source: Belite Bio, Inc

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month...
August 07, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Registered Direct Offering of $15 Million

The offering was to a single large existing institutional shareholder SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug...
August 06, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...
August 04, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...
July 23, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the BTIG Virtual Biotechnology Conference

SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...
July 02, 2025 03:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

- 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio,...
May 21, 2025 03:00 ET | Source: Belite Bio, Inc

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a...
May 13, 2025 21:00 ET | Source: Belite Bio, Inc

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1)...
May 12, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in Four Upcoming Investor Conferences

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...